Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives

References

• AlterMJPrevention of spread of hepatitis CHepatology2002365 Suppl 1S93S9812407581
   PubMed Web of Science ®Google Scholar
• MenniniFSMarcellusiAAndreoniMHealth policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in ItalyClinicoecon Outcomes Res2014630331024971024
   PubMedGoogle Scholar
• FagiuoliSLucàMGMaginiGDe GiorgioMPuntare sulla prevenzione delle epatiti come strategia per evitare che vi sia progressione dell’epatocarcinoma [Focusing on prevention of hepatitis as a strategy to ensure that there is progression of HCC]. Il Sole 24 Ore Sanità, giugno2013 Italian
   Google Scholar
• LeeMHYangHIYuanYL’ItalienGChenCJEpidemiology and natural history of hepatitis C virus infectionWorld J Gastroenterol201420289270928025071320
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and ControlTechnical Report Hepatitis B and C in the EU neighborhood: prevalence, burden of disease and screening policies92010 Available from: http://www.ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdfAccessed April 16, 2016
   Google Scholar
• European Association for the Study of the LiverEASL recommendations on treatment of hepatitis CJ Hepatol201563119923625911336
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (AIFA)Pubblicato il nuovo Algoritmo per la terapia dell’Epatite C cronica; 2015 [Published the new algorithm the Hepatitis C chronic therapy; 2015] Available from: http://www.agenziafarmaco.gov.it/it/content/pubblicato-il-nuovo-algoritmo-la-terapia-dell%E2%80%99epatite-c-cronicaAccessed April 16, 2016 Italian
   Google Scholar
• Italian Medicines Agency (AIFA)Aggiornamento dati Registri AIFA DAAs 28 dicembre 2015 [Update Data Registers AIFA DAAs December 28, 2015] Available from: http://www.agenziafarmaco.gov.it/sites/default/files/Aggiornamento_dati_Registri_AIFA_DAAs_28.12.2015.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Associazione Italiana per lo Studio del Fegato (AISF)Libro Bianco AISF 2011: Proposta per un piano nazionale per il controllo delle malattie epatiche. Definizione ambiti e possibili interventi; 2011 [AISF White Book 2011: Proposal for a national plan for disease control liver. Defining scopes and possible interventions; 2011] Available from: http://www.webaisf.org/media/13891/libro-bianco-aisf-2011.pdfAccessed April 16, 2016 Italian
   Google Scholar
• MarcellusiAVitiRCaponeAMenniniFSThe economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness modelEur Rev Med Pharmacol Sci20151991610162026004601
   PubMed Web of Science ®Google Scholar
• VietriJPrajapatiGEl KhouryACThe burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countriesBMC Gastroenterol2013131623324473
   PubMed Web of Science ®Google Scholar
• MenniniFSMarcellusiAVitiRAndreoniMDisponibilità a pagare e innovazione: il caso dei farmaci anti-HCV nel Sistema Sanitario Italiano [Willingness to pay, and innovation: the case of anti-HCV drugs in the Italian health service]GRHTA2015226977 Italian
   Google Scholar
• AnsaldiFBruzzoneBSalmasoSDifferent seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in ItalyJ Med Virol200576332733215902713
   PubMed Web of Science ®Google Scholar
• MarascioNMateraGQuirinoAEleven-year distribution pattern of hepatitis C virus in southern ItalyJ Pathog2012201263109522934187
   PubMedGoogle Scholar
• Piattaforma Italiana per lo studio della Terapia delle Epatiti Virali (PITER) [Italian platform for the study of the Therapy of Viral Hepatitis (PITER)] Available from: http://www.iss.it/piter/?lang=1&id=163&tipo=3Accessed April 16, 2016 Italian.
   Google Scholar
• Italian National Institute of StatisticsDemo: demography in figures database2015 Available from: http://demo.istat.it/pop2015/index.htmlAccessed April 16, 2016
   Google Scholar
• GardiniIEpatite C e sostenibilità dei farmaci innovativi [Hepatitis C and sustainability of innovative medicines]Care i costi dell’assistenza e risorse economiche2015614 Available from: http://careonline.it/wp-content/uploads/2015/12/Gardini_Care_6_2015.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Italian Ministry of JusticeStatistics: prisoners in the Italian jails, situation on the 31st of December 2015 Available from: https://www.giustizia.it/giustizia/it/mg_1_14_1.wp?previsiousPage=mg_1_14&contentId=SST1204480Accessed April 16, 2016
   Google Scholar
• Regional Health Agency of TuscanyLa salute dei detenuti in Italia: i risultati di uno studio multicentrico. Documenti dell’Agenzia Regionale di Sanità della Toscana, 83 [The health of detainees in Italy: results of a multicenter study. Documents of the Regional Agency of Health of Tuscany, 83]42015 Available from: https://www.ars.toscana.it/files/pubblicazioni/Volumi/2015/carcere_2015_definitivo.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Italian Ministry of Health, cited by adnkronos Available from: http://www.adnkronos.com/salute/sanita/2014/09/12/niente-ticket-sul-delle-ricette-per-esami-visite-arrivo-una-riforma-del-sistema_XL3hfVYler-10l49USc9JXN.html?refresh_ceAccessed April 16, 2016 Italian
   Google Scholar
• Italian Medicines Agency (AIFA)Lista Centri autorizzati alla prescrizione dei farmaci antivirali per l’epatite C – Aggiornamento [List authorized centers to prescription antiviral drugs for hepatitis C - Update]12302015 Available from: http://www.agenziafarmaco.gov.it/it/content/lista-centri-autorizzati-alla-prescrizione-dei-farmaci-antivirali-l%E2%80%99epatite-c-aggiornamento-Accessed April 16, 2016 Italian
   Google Scholar
• MühlbergerNSchwarzerRLettmeierBSroczynskiGZeuzemSSiebertUHCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityBMC Public Health200993419161623
   PubMed Web of Science ®Google Scholar
• McEwanPWardTWebsterSKalsekarABrennerMYuanYEstimating the cost-effectiveness of 12 weeks of daclatasvir+sofosbuvir in patients chronically infected with HCV genotype 3Poster presented at the 20th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)May 16–20, 2015Philadelphia, USA Available at: http://www.ispor.org/research_pdfs/49/pdffiles/PIN73.pdfAccessed June 27, 2016
   Google Scholar
• TheinHHYiQDoreGJKrahnMDEstimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regressionHepatology200848241843118563841
   PubMed Web of Science ®Google Scholar
• ShepherdJJonesJHartwellDDavidsonPPriceAWaughNInterferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluationHealth Technol Assess20071111120517346498
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (AIFA)Social Affairs Commission audition11162015 Available from: http://webtv.camera.it/evento/8620Accessed April 16, 2016
   Google Scholar
• Agenzia Italiana del FarmacoDetermina 12 novembre 2014. Regime di rimborsabilità e prezzo del medicinale per uso umano «Sovaldi» (sofosbuvir), autorizzata con procedura centralizzata europea dalla Commissione europea (Determina n. 1353/2014). (14A09382) (GU Serie Generale n. 283) (del 5-12-2014) [Determines 12 November 2014. reimbursement and price of the medicinal products for human use “Sovaldi” (Sofosbuvir), authorized by the European centralized procedure European Commission (Determines n 1353/2014). (14A09382) (OJ Series General 283) (of 05.12.2014)] Available from: http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2014-12-05&atto.codiceRedazionale=14A09382&elenco30giorni=falseAccessed April 16, 2016 Italian
   Google Scholar
• Agenzia Italiana del FarmacoDetermina 8 maggio 2015. Regime di rimborsabilità e prezzo del medicinale per uso umano «Harvoni (ledipasvir/sofosbuvir)» (Determina n. 544/2015) (15A03674) (GU Serie Generale n. 109) (del 13-5-2015) [Determines May 8, 2015. Regime of eligibility and price of the medicinal products for human use “Harvoni (ledipasvir/sofosbuvir)” (determines n 544/2015) (15A03674) (OJ General Series 109) (of 05.13.2015) Available from: http://www.gazzettaufficiale.it/eli/id/2015/05/13/15A03674/sg%20;jsessionid=DZfSl94qS9LREa1djBOfvQ__ntc-as1-guri2bAccessed April 16, 2016 Italian
   Google Scholar
• International Monetary FundWorld Economic Outlook Database102015 Available from: http://www.imf.org/external/pubs/ft/weo/2015/02/weodata/index.aspxAccessed April 16, 2016
   Google Scholar
• Società Italiana di Medicina Generale e delle Cure Primarie (SIMG), Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Malattie Infettive e Tropicali (SIMIT)Documento intersocietario SIMG-AISF-SIMIT sul virus dell’epatite C; 2009 [InterNGO document SIMG-AISF-SIMIT on hepatitis C; 2009] Available at: https://www.simg.it/Documenti/Rivista/2009/04_2009/4.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Gastroenterologia (SIGE)Programma Nazionale di Educazione e Competenza Continua, Epatocarcinoma, Corso di Formazione e di Aggior-namento Chianciano Terme (SI), 30–31 Gennaio; Febbraio 1, 2008 [Italian society of Gastroenterology (GETS). the National Education Program Competence and Continue, Hepatocellular carcinoma, Training Course and Update Chianciano Terme (SI), 30 to 31 January; February 1, 2008] Available from: http://www.webaisf.org/media/4415/sillabus2008.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Associazione Italiana di Oncologia Medica (AIOM)Linee guida Epatocarcinoma. Edizione 2015 [Italian Medical Oncology Association, Hepatocellular carcinoma guidelines. 2015 edition] Available from: https://www.aiom.it/C_Common/Download.asp?file=/$Site$/files/doc/lg/2015_lg_aiom_epatocarcinoma.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Associazione Italiana per lo Studio del Fegato (AISF)Trapianto di fegato non urgente dell’adulto – Raccomandazioni della Commissione di Studio A.I.S.F; 2004 [Adult liver transplant not urgent - Commission Recommendations Study A.I.S.F; 2004] Available from: http://www.webaisf.org/media/8065/documento_trapianto.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Italian Ministry of HealthSistema Informativo Trapianti – Attività di donazione al; dicembre 31, 2014 [Information System Transplantation activities - the donation; December 31, 2014] Available from: http://www.trapianti.salute.gov.it/imgs/C_17_pubblicazioni_2316_allegato.pdfAccessed April 16, 2016 Italian
   Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med2013368201878188723607594
   PubMed Web of Science ®Google Scholar
• LawitzEPoordadFBrainardDMSofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 studyHepatology2013581380A
   Web of Science ®Google Scholar
• LawitzELalezariJPHassaneinTSofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialLancet Infect Dis20131340140823499158
   PubMed Web of Science ®Google Scholar
• FosterGRPiankoSBrownAEfficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infectionGastroenterology201514961462147026248087
   PubMed Web of Science ®Google Scholar
• HézodeCAsselahTReddyKROmbitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trialLancet201538599862502250925837829
   PubMed Web of Science ®Google Scholar
• AfdhalNZeuzemSKwoPLedipasvir and sofosbuvir for untreated HCV genotype 1 infectionN Engl J Med2014370201889189824725239
   PubMed Web of Science ®Google Scholar
• NelsonDRCooperJNLalezariJPAll-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyHepatology20156141127113525614962
   PubMed Web of Science ®Google Scholar
• A.O.U. San Luigi GonzagaAffidamento della fornitura delle specialità medicinali per il trattamento dell’infezione cronica da virus HCV, “DAKLINZA” Società Bristol-Myers Squibb s.r.l., “HARVONI” Società Gilead Sciences S.R.L., “VIEKIRAX” e “EXVIERA” Società Abbvie s.r.l. (DET. 307) (del 19-06-2015) [Supply of specialties medicines for the treatment of chronic HCV, “DAKLINZA” Bristol-Myers Squibb Company LTD, “HARVONI” Company Gilead Sciences S.R.L., “VIEKIRAX” and “EXVIERA” Company Abbvie LTD (DET. 307) (the 06/19/2015)] Available from: http://www.sanluigi.piemonte.it/delibere/DL33/Allegati/9781.pdfAccessed April 16, 2016 Italian
   Google Scholar
• Agenzia Italiana del FarmacoDetermina 25 novembre 2011. Regime di rimborsabilità e prezzo di vendita del medicinale Pegasys (peginterferone alfa-2a) autorizzata con procedura centralizzata europea dalla Commissione europea con la decisione del 29/06/011 (Determinazione/C 2753/2011) (Gazzetta n. 285) (del 7-122011) [Determines 25 November 2011. Scheme reimbursement and price of Pegasys (peginterferon alfa-2a) authorized by the European Commission (EMA) on 29/06/011] Available from: http://www.gazzettaufficiale.biz/atti/2011/20110285/11A15734.htmAccessed April 16, 2016 Italian
   Google Scholar
• Agenzia Italiana del FarmacoDetermina 18 gennaio 2013. Regime di rimborsabilità e prezzo di vendita del medicinale per uso umano «Ribavirina Mylan» (ribavirina) autorizzata con procedura centralizzata europea dalla Commissione europea (Determina n. 38/2013) (13A00836) (GU Serie Generale n. 30) (del 5-2-2013) [Regime of eligibility and price of the human use drug “Ribavirin Mylan” (ribavirin) authorized by the European Commission] Available from: http://www.gazzettaufficiale.it/eli/id/2013/02/05/13A00836/sgAccessed April 16, 2016 Italian
   Google Scholar
• Regione CalabriaFarmaci del PHT −12° Aggiornamento Tabella Prezzi – Tabelle relative al 12° aggiornamento dei farmaci del PHT di cui agli Accordo-Quadro stipulati tra la Regione Calabria e le Aziende Farmaceutiche e ratificati con decreto n. 3472 (del 20-4-2015) [The PHT medication −12° Update Table Prices - Tables on the 12th update of the PHT drugs where the Framework Agreement signed between the Region of Calabria and Companies Pharmaceutical and ratified by decree n 3472 (of 04.20.2015)] Available from: http://www.regione.calabria.it/sanita/allegati/deceti_2015/farmaci_del_pht_-12_aggiornamento_tabella_prezzi_-.pdfAccessed April 16, 2016 Italian
   Google Scholar